Silibinin, a commonly used therapeutic agent for non‐alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19

Silibinin is used to treat non-alcohol fatty liver disease (NAFLD) despite having rapid liver metabolism. Therefore, we investigated the role of the intestine in silibinin mechanism of action.